Tiefenbacher Group draws attention to Rare Disease Day.
Today we are focusing on awareness and generating change for the 300 million people worldwide living with rare diseases. Treatment for many rare diseases is insufficient, that´s why we at Tiefenbacher Group are dedicated to protecting and improving lives through innovative healthcare solutions.
In the fight against rare diseases, we are committed to deliver high-quality pharmaceuticals which are better affordable, better available, and better than before. We are glad to offer a refined medication for Wilson Disease, Amifampridine for Lambert-Eaton Myasthenic Syndrome (LEMS) as well as a novel dosage form for a known medicine for Cystinosis – just to name a few of our innovative solutions.
Our culture of caring is essential to achieving our goal of significantly making a difference in the daily lives of people around the world. Therefore we will continue to focus on supporting initiatives like the rarediseaseday organisation that are in line with our values and beliefs.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world:
We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
